Hallam, Dean and Collin, Joseph and Bojic, Sanja and Chichagova, Valeria and Buskin, Adriana and Xu, Yaobu and Lafage, Lucia and Otten, Elsje, G. and Anyfantis, George and Mellough, Carla and Przyboski, Stefan and Alharthi, Sameer and Korolchuk, Viktor and Lotery, Andrew and Saretzki, Gabriele and McKibbin, Martin and Armstrong, Lyle and Steel, David and Kavanagh, David and Lako, Majlinda (2017) 'An iPSC patient specific model of CFH (Y402H) polymorphism displays characteristic features of AMD and indicates a beneficial role for UV light exposure.', Stem cells., 35 (11). pp. 2305-2320.

Further information on publisher’s website:
https://doi.org/10.1002/stem.2708

Publisher’s copyright statement:
© 2017 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Additional information:

Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a link is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the full DRO policy for further details.
Title: An iPSC patient specific model of CFH (Y402H) polymorphism displays characteristic features of AMD and indicates a beneficial role for UV light exposure

Dean Hallam¹, Joseph Collin¹, Sanja Bojic¹, Valeria Chichagova¹, Adriana Buskin¹, Yaobo Xu¹, Lucia Lafage¹, Elsje. G. Otten², George Anyfantis¹, Carla Mellough¹, Stefan Przyborski³, Sameer Alharthi⁴, Viktor Korolchuk⁵, Andrew Lotery⁵, Gabriele Saretzki², Martin McKibbin⁵, Lyle Armstrong¹, David Steel¹, David Kavanagh¹ & Majlinda Lako¹

Author Affiliations:

¹Newcastle University, Institute of Genetic Medicine, International Centre for Life, Central Parkway, Newcastle upon Tyne, United Kingdom.
²Newcastle University, Institute for Cell & Molecular Biosciences and Institute for Ageing, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL
³Department of Biosciences, Durham University, Durham, UK
⁴King Abdulaziz University, Princess Al Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, Saudi Arabia
⁵University of Southampton, Clinical and Experimental Sciences, Faculty of Medicine, Southampton, UK.
⁶Leeds Teaching Hospital NHS, Leeds, UK

Corresponding Author: Majlinda Lako, PhD
Prof. of Stem Cell Sciences
Newcastle University
Institute of Genetic Medicine
International Centre for Life
Central Parkway
Newcastle upon Tyne NE1 3 BZ
United Kingdom
Phone: 00 +44191 2418688

Keywords: AMD, Complement factor H, iPSC, RPE.
Abstract

Age related macular degeneration (AMD) is the most common cause of blindness, accounting for 8.7% of all blindness globally. Vision loss is caused ultimately by apoptosis of the retinal pigment epithelium (RPE) and overlying photoreceptors. Treatments are evolving for the wet form of the disease, however these do not exist for the dry form. Complement factor H (CFH) polymorphism in exon 9 (Y402H) has shown a strong association with susceptibility to AMD resulting in complement activation, recruitment of phagocytes, retinal pigment epithelium (RPE) damage and visual decline. We have derived and characterised induced pluripotent stem cell (iPSCs) lines from two patients without AMD and low risk genotype and two patients with advanced AMD and high risk genotype and generated RPE cells that show local secretion of several proteins involved in the complement pathway including factor H (FH), factor I (FI) and factor H like 1 (FHL-1). The iPSC RPE cells derived from high risk patients mimic several key features of AMD including increased inflammation and cellular stress, accumulation of lipid droplets, impaired autophagy and deposition of “drüsen” like deposits. The low and high risk RPE cells respond differently to intermittent exposure to UV light which leads to an improvement in cellular and functional phenotype only in the high risk AMD-RPE cells. Taken together our data indicate that the patient specific iPSC model provides a robust platform for understanding the role of complement activation in AMD, evaluating new therapies based on complement modulation and drug testing.
**Introduction**

Age related macular degeneration (AMD) is the most common cause of blindness in the developed world, affecting one in three people by age 75 and is characterised by a loss of central vision, affecting the macular area of the retina. It accounts for 50% of blind and partially sighted registration with an estimated prevalence of ~600,000 significantly visually impaired people in the UK and over 8 million worldwide (1-4). 70,000 new diagnoses are made every year in UK and 13% of people aged over 80 are affected by late stage AMD. The number of AMD affected people in UK is expected to rise to 1.3 M by 2050 with healthcare costs rising to 16.4 billion during 2010-2020 (5). Visual loss associated with AMD is caused by apoptosis of the retinal pigment epithelium (RPE) and overlying photoreceptors. AMD occurs in two forms: “dry” AMD where cellular debris, called drüsen accumulates between the RPE and Bruch’s membrane (BrM), appearing as yellow specks on the retina. “Wet” AMD is usually characterised by aberrant blood vessel growth and encroachment from the choroid underneath the retina although it can also originate from the inner retinal vasculature. Treatments are evolving for wet AMD including anti-VEGF treatments, photodynamic and laser therapy (6-8); however there are no effective treatments to prevent progression of the underlying disease process and advanced dry AMD.

AMD is a multifactorial progressive disease with a complex interaction between environmental, metabolic, hereditary factors and chronic innate immune activation (9). A variety of alleles and haplotypes associated with early and late AMD have been identified from genome wide association studies (GWAS) (10-13), but the precise roles of these genes and the mechanisms by which they increase disease risk are ill defined. One of the most significant genetic findings for AMD has been the complement factor H (CFH) polymorphisms. Complement Factor H (FH) protein functions by limiting the formation of C3 convertase of the complement system and by promoting the degradation of C3b to iC3b. Failure to control the activity of C3 convertase results in overproduction of C3b and C3a causing a shift in the complement cascade to its terminal lytic pathway. A significantly
deleterious consequence of this is the formation of the anaphylotoxin, C5a and the membrane attack complex both of which deliver potent inflammatory signals. The T>C substitution in exon 9 (Y402H) of the CFH gene is strongly associated with susceptibility to AMD and has led to recognition of the importance of complement activation in AMD pathogenesis (10). There is now evidence from large case-control association studies to confirm association with a variety of other complement cascade genes including CFHR1-3, CFI, CFB, C3, and C9 (10, 11). The polymorphisms within the 10q26 gene loci containing the PIEKHA1/HTRA1/ARMS2 genes have also consistently demonstrated strong associations with AMD in GWAS (10, 12). In addition to data gathered from large genetic cohorts, biochemical and molecular studies have provided substantial evidence to support an important role for complement activation in AMD. This is illustrated by the presence of activators and regulators of the complement system in drüsen (14) and the increased expression of membrane attack complex (MAC) proteins in choriocapillaris and BrM of aged individuals as well as those with the Y402H polymorphism (15-17).

The Y402H polymorphism can confer >5 fold increase risk of developing AMD and is present in approximately 30% of people of European descent. Although FH protein is synthesised by the choroid, it is not able to diffuse passively through BrM into the retina; however its alternatively spliced, truncated form, named FH-like protein 1 (FHL-1), is able to do so (18). FHL-1 retains all the necessary domains for complement regulation and binds to BrM through interactions with heparan sulphate (18-20). The Y402H polymorphism affects the ability of both FH and FHL-1 to bind to heparan sulphate (21). Furthermore, FH and lipoproteins compete for binding to heparan sulphate in BrM (22), thus it has been suggested that impaired binding of FH/FHL-1 to heparan sulphate in individuals with Y402H polymorphism results in fewer binding sites for FH/FHL-1, increased C3b depositions, lipoprotein accumulation and failure to regulate complement activation, leading to recruitment of mononuclear phagocytes, RPE damage, and visual function decline.
Recent advances in the field of induced pluripotency have permitted generation of patient specific induced pluripotent stem cells (iPSCs) which have the ability to differentiate into cells of any tissue type including photoreceptors and RPE (23). The ability to produce large quantities of functional patient-specific retinal cells from iPSCs offers an unparalleled chance to elucidate disease mechanisms and evaluate new therapeutic agents. Since the pathogenesis of AMD is largely unknown, creating a disease model using iPSC technology could be a valuable tool to address fundamental questions about disease biology as well as creating a biological tool to perform drug discovery and toxicity screening. The validity of this approach has been illustrated by two recent publications reporting derivation of iPSCs from AMD patients with ARMS2/HTRA1 high risk genotypes displaying reduced SOD2 defence, rendering RPE more susceptible to oxidative damage (24, 25). We focused on derivation and characterisation of iPSC from individuals homozygous for the low and high risk CFH (Y402H) polymorphism. When compared to iPSC-RPE derived from age matched control low risk individuals, the high risk iPSC-RPE cells show a range of cellular, ultrastructural and functional deficiencies that mimic several key features of AMD including increased inflammation, hallmarks of cellular stress, accumulation of lipid droplets and deposition of “drüsen” like deposits. Exposure to intermittent ultra violet light (UV) elicited different responses from low and high risk RPE cells and in the latter revealed an improvement in the cellular and ultrastructural features associated with AMD. Together our data, suggest that the patient specific iPSC disease modelling provides a robust tool to assess potential therapeutic agents to treat AMD before long expensive trials.

Results

Generation of iPSCs from high risk AMD donors and unaffected controls

To investigate how the Y402H polymorphism in CFH leads to the pathology associated with AMD, DNA was extracted from donor cell fibroblasts and sequenced to detect single
nucleotide polymorphisms in the CFH, HTRA1 and ARMS2 genes (Supplementary Figure 1, A). The two homozygous low risk donors were selected on the basis of low risk for all three SNP’s rs11200638 (HTRA1), rs1061170 (CFH) and rs10490924 (ARMS2) and no clinical manifestation of AMD. The high risk donors were specifically selected as having advanced AMD with unilateral wet AMD and reticular pseudodrüsen (a known high risk feature for both types of advanced AMD) in their fellow eyes (Supplementary Figure 1, B-C’) and high risk SNP for CFH and low risk HTRA1 and ARMS2. The high risk CFH in combination with low risk HTRA1 polymorphism has been consistently associated with central drüsen formation in the older age group (26).

iPSCs were generated from dermal fibroblasts using non-integrative Sendai viral vectors expressing Yamanaka reprogramming transgenes. Between twenty and thirty clones were generated from each donor. At least three clones from each individual were expanded, adapted to feeder free culture conditions and thoroughly characterised using well established tests of pluripotency including expression of markers by immunocytochemistry (SSEA4 & OCT4, Supplementary Figure 2, A), RT-PCR (NANOG, KLF4, C-MYC & SOX2) Supplementary Figure 2, B) and flow cytometry (SSEA4 & OCT4, Supplementary Figure 2, C), ability to differentiate into all three germ layers in vitro (SMA, TUJ1 & AFP; Supplementary Figure 2, D) and in vivo (Supplementary Figure 2, E), clearance of Sendai Transgenes (Supplementary Figure 2, F) and genetic identity to parent fibroblasts (Supplementary Figure 2, G). One clone from each patient was further selected for differentiation studies. CytoSNP analysis indicated no chromosomal re-arrangements, losses or duplications. Our RT-PCR analysis also indicated that CFH and FHL-1 are not expressed in iPSCs (Supplementary Figure 3, A).

Establishing iPSC-RPE from high risk AMD patients and unaffected controls
iPSCs were differentiated to RPE using a defined serum and feeder free protocol described in the methods section. The RPE patches were mechanically isolated and expanded on laminin coated trans-well inserts or tissue culture plates. Hexagonal cells with pigmentation both visible macro and microscopically (Figure 1, A, B), which expressed the putative RPE cell marker ZO-1, CRALBP and BEST1 (Figure 1, C). Polarity in the RPE cells is important for their physiological function, we checked the presence of Na\textsuperscript{+} K\textsuperscript{+}-ATPase in both low and high risk iPSC-RPE cells and showed apical localisation in both (Figure 1, D). iPSC-RPE cells also secreted pigment epithelium-derived factor (PEDF) also known as serpin F1 (SERPINF1) in a physiologically similar fashion to adult RPE (27) (Figure 1, E) all cultures. RPE cells form a tight barrier in the retina which can be measured by trans-epithelial resistance (TER). We observed no significant differences in TER between RPE derived from high or low risk AMD individuals (Figure 1, F). Phagocytosis assays also indicated that iPSC-RPE were able to phagocytose bovine rod outer segments with no differences observed between low and high risk AMD donors (data not shown).

Expression of Complement Factor H, Factor H like protein 1, Factor I and C3b in iPSC-RPE cells.

Expression of, FH/FHL-1 (Figure 2, A), FI (Figure 2, B) and C3 proteins (Figure 2, C) were detected in RPE conditioned supematants derived from both high and low risk cultures, indicating that iPSC-RPE cells secrete the main component and regulators of the alternative complement pathway. Importantly the excreted proteins FH and FI were shown to be functional, indicated by the breakdown of C3b to iC3b (Figure 2, D). CFH, FHL-1, CFI and C3 expression were also confirmed at the mRNA level utilising qRT-PCR (Figure 3, A, B, C, D & E). CFI, CFH and FHL-1 were all upregulated in high risk iPSC-RPE cells (Figure 3, A, B, C), a trend also observed in iPSC-RPE derived from HTRA1/ARMS2 risk genotypes (25). Interestingly C3 was down regulated in high-risk iPSC-RPE, while C5 showed no significant
difference (Figure 3, C, D). Together these results add to the evidence for local complement synthesis in the eye as previously documented in the literature (28, 29).

**Gene expression profiles of cytokines in AMD and control iPSC-RPE**

High-risk iPSC-RPE had reduced gene expression of mitochondrial Superoxide dismutase 2, (SOD2) (Figure 3, F), which acts to transform superoxide, a toxic by-product of oxidative phosphorylation, into less harmful hydrogen peroxide and diatomic oxygen. It has also been reported that ARMS2/HTRA1 polymorphism leads to compromised superoxide dismutase 2 response (23) while knockout of SOD2 in mice is used as an early model of AMD (30).

*APOE* (Apolipoprotein E), a transporter of lipoproteins and fat-soluble vitamins, and *TNF-α* (Tumour necrosis factor) a cytokine involved in systemic inflammation and implicated in downregulation of *OTX2* (31), showed increased expression in high risk donors (Figure 3, G, H), however Interleukin-18 (*IL18*), a cytokine which can suppress *VEGF* expression and has been associated with AMD (32), showed no significant difference between genotypes (Figure 3, I). No significant changes between genotypes were observed for vascular endothelial growth factor (*VEGF*) expression (Figure 3, J). Interleukin 1β (*IL1β*) has a broad spectrum of mediation in cellular function and has been implicated as an effector of the inflammatory response (33). We noted a significant difference between genotypes with high-risk donors expressing *IL1β* at a higher level than low risk RPE (Figure 3, K). Elevated levels of *IL-6* are found in the vitreal fluid of AMD patients and have been used as predictors of AMD progression (34), however we did not detect any difference in IL6 between genotypes suggesting that the release of this cytokine is likely from another source such as microglia (Figure 3, L). Orthodenticle homeobox 2 (OTX2) controls essential, homeostatic RPE genes. There was a slight decrease (although not significant) in OTX2 in high-risk donors, perhaps linked to *TNF-α* expression as previously stated (Figure 3, M). *RPE65* expression remained constant in both genotypes (Figure 3, N).
To further probe into the differences between high and low risk RPE cells, we performed RNA-seq studies which identified 41 genes residing in the 0.3% percentile and 99.7% percentile, equating to a -5.532 fold change or greater and 5.66 or greater respectively (Supplementary Figure 3, C). This analysis revealed the upregulated expression of CGA (Glycoprotein hormones α-chain) in RPE cells derived from high-risk donors (Supplementary Figure 3, C). Currently there is no documented expression of CGA in RPE cells, however the expression its of receptor (GNRHR, Gonadotropin-releasing hormone receptor) has been detected in retinal tissues (35). Recoverin (RCVRN) expression, which marks photoreceptor precursors, was also upregulated in high-risk donors (Supplementary Figure 3, C). It is of interest to note that expression of RCVRN has been observed in RPE cells which were induced to transdifferentiate to photoreceptors via overexpression of Neurogenin 1 or 3 (34). RPE cells undergoing this transition have been noted to retain pigmentation while displaying an elongated cell body and RCVRN expression in aPVMD2-ngn1 mouse (36, 37). It is currently unclear whether increased RCVRN expression in high risk AMD-RPE is related to cell fate changes, or to an impaired wound healing response and epithelial to mesenchymal transition which has already been reported in AMD-RPE (38).

One family of genes was disproportionately represented in the low risk donor including members of the Wnt and Cadherin signalling pathways [Protocadherin gamma-A3 (PCDHGA3), Protocadherin beta-8 (PCDHB8), Protocadherin gamma-A6 (PCDHGA6) & Putative protocadherin beta-18 (PCDHB18P)], implying that low risk donors may find it easier to form cell-cell junctions when compared to high risk RPE, thus corroborating previously published data showing disrupted cell to cell junctions and induction of AMD associated pathological changes in light exposed RPE cells (39).

When all genes with > 1.5 fold expression changes between the high and low risk iPSC RPE were analysed using Enrichr, (OMIM disease) (40), macular degeneration, diabetes mellitus type 2 and protein glycosylation disorder diseases were found to be overrepresented in the
RNA-seq dataset \( (p=0.05475, \text{ Supplementary Figure 3 B}) \). Glycosyltransferases are responsible for post-translational glycol modification of proteins, and this is considered a location specific modification as the enzymes required are normally compartmentalised. Glycosylation status is suggested to be important for efficient transport/diffusion of FHL-1 though BrM, FHL-1 is normally non-glycosylated and passes easily (41), while glycosylated CFH does not. Interfering with this status could be detrimental to location and diffusion characteristics. Additionally, advanced glycosylation end products (AGE) are a classical indication of an aged RPE cell layer (42). Together these data suggests that the \textit{in vitro} iPSC-RPE model we have created mimics the disease at the molecular level.

\textbf{C5b-9 deposition and APOE co-localisation in AMD iPSC-RPE}

Many investigations have described the proteomic and lipid composition of drüsen (43). APOE is ubiquitously associated with drüsen formation and shown to comprise 36% of all proteins found extracellularly (43). The terminal complement complex (TCC) \( (C5b-C6-C7-C8-C9, [C5b-9]) \) is comprised of five proteins, C5b, C6, C7, and C8, with the fifth, C9 forming a transmembrane ring structure. We found the presence of aggregates that either contained ApoE, C5b-9 or both proteins in low and high risk iPSC-RPE; however the size of deposits containing both ApoE and C5b 9 was larger in the high risk RPE (\textbf{Figure 4, A-D}). Significantly, larger lipid globules were also detected in high risk donors compared with low risk (\textbf{Figure 4, E & F}).

\textbf{Ultrastructural changes to AMD iPSC-RPE}

Transmission electron microscopy (TEM) showed that the length of microvilli was reduced in RPE derived from the high risk donors (\textbf{Figure 5, A}). The mitochondrial number also decreased (\textbf{Figure 5, C}), however the area covered by them was slightly larger in high risk
donors (Figure 5, B) suggestive of fewer but larger mitochondria which could be the result of age related mitochondrial dysfunction or stress (44). Long range PCR assays indicated the absence of mtDNA deletions in the fibroblasts and RPE derived from both low and high risk individuals (data not shown). We also observed the formation of asymmetric vacuoles (marked with red stars) almost exclusively in RPE generated from high-risk donors (Figure 5, D, E & F). These vacuoles, which are indicative of “adaptive survival” in response to environmental or oxidative stress, have also been observed in a SOD2 knockdown mouse model of early AMD (28). They have the potential to lead to vacuolation-mediated cell death, however our flow cytometric analysis did not indicate significant changes in apoptosis between low and high risk AMD iPSC-RPE (data not shown).

**Autophagy is upregulated in high risk AMD iPSC-RPE cells**

Due to the increased lipid build-up and ultrastructural changes we suspected that autophagy may have a role in AMD pathogenesis. It has also been documented previously that dysregulated autophagy may sensitise RPE cells to oxidative stress (45). Autophagy is associated with intra/inter cellular waste removal and is upregulated during nutrient starvation and general stress response. In donor fibroblasts no difference in expression of two key autophagy markers, LC3 puncta and p62 aggregates was observed between low and high risk donors (Figure 6 A, B, C, D), however p62 intensity was higher in low risk donors (Figure 6, E), and localised to the nuclei. In the corresponding iPSC-RPE, LC3 puncta and p62 aggregates were greatly upregulated in high risk RPE (Figure 6 F, G, H, I) along with the intensity of p62, which was also increased (Figure 6, J), which potentially suggests a block in autophagy in high risk RPE-iPSC.

**The response of low and high risk AMD-RPE cells to UV exposure**
UV can induce the generation of ROS derived from diatomic oxygen (O$_2$), superoxide anion (O$_2^-$), hydroxyl and peroxyl radicals, resulting in DNA damage. The retina is highly susceptible to photochemical damage due to continuous light and UV exposure. This photochemical induction is exacerbated by the retinal oxygen tension (70 mmHg), which is higher than many other tissues, thereby increasing the probability of ROS formation. Although the relationship between UV light exposure and AMD is unclear, epidemiological evidence indicates an association between the severity of light exposure and the occurrence of AMD (46). Light in the visible UV spectrum (441 nm) is deleterious for RPE cells, being the most energetic radiation reaching the macula and causes photo-oxidation generating reactive photoproducts including N-retinyldiene-N-retinylethanolamine (A2E), DNA oxidation, and cell apoptosis (47, 48). Drüsen and outer segments are composed largely of lipids (polyunsaturated fatty acids) and are particularly vulnerable to photo-oxidation leading to a chain reaction mechanism of lipid peroxidation and peroxide organic free radical production (49).

To investigate whether UV exposure acts to exacerbate the gene expression, functional or structural defects observed in RPE cells derived from AMD patients, we exposed iPSC-RPE cells continuously to 0.0045 mW/cm$^2$ of 390-410nm light for 1 hour each day for 5 days which resulted in an increase in the concentration of intracellular reactive oxygen species and decreased mitochondrial membrane potential (data not shown). Pigmentation levels can affect the absorption of UV light, however pigmentation levels between low and high risk donors did not differ significantly (p=0.5; Supplementary figure 3, D). IL6 expression, a cytokine previously associated with AMD (50), was increased in response to UV in both low and high risk iPSC-RPE cells (Figure 7, A). SOD2, VEGF, IL18, CFH and FHL-1 expression increased only in the high risk RPE cells (Figure 7, B, C, D, E), suggesting inflamasome activation. The expression of CFI was upregulated only in the low risk iPSC-RPE cells (Figure 7, F). No change in APOE, TNF-α, IL1β, CFH, C3, C5, RPE65 or OTX2 expression was observed in both high and low risk iPSC-RPE upon UV treatment (Figure 7, G, H, I, J,
K, L, M, N). Mitochondrial area decreased in both low and high-risk iPSC-RPE when exposed to 390-410nm UV light (Figure 7, P), while the overall number of mitochondria remained similar (Figure 7, Q). While there was no significant increase in the number of vacuoles or drüsen-like deposits in low risk iPSC-RPE cells, in the high risk iPSC-RPE both parameters decreased significantly (below levels observed in the low risk iPSC-RPE cultures; Figure 7, R and 7, S and Supplementary Figure 3 E), which we hypothesise is possibly due to increased expression of SOD2 and other protective complement proteins (FHL-1, CFH) in response to UV exposure. Photobiomodulation or optogenetics has shown that specific wavelengths of light exhibit physiological effects on biological systems. Near-infra-red for example enhances mitochondrial activity via activation of cytochrome oxidase [a photoacceptor, due to four redox active metal centres, presumed to convert bosons (photons) to fermions (electrons and positrons)], increases in electrons leads accelerated electron transport and increased generation of ATP (51). Currently a photoacceptor, such as cytochrome oxidase, for 390-410nm light has yet to be identified, traditionally studies have focused on the “optical window” biased on absorption and scattering of light in tissues, which is higher for both in the blue end of the spectrum, however the optical properties of the cornea decrease this scattering effect making blue light physiologically relevant to the retina. Additionally microvilli length in high-risk donor cells increased in response to UV (Figure 7, O). Together our data suggest that low and high risk iPSC-RPE cells respond differently to UV light exposure and set precedence for using iPSC-RPE disease modelling as a platform for testing existing and new therapeutic regimes.
**Discussion**

To date there are no effective treatments that target the underlying disease process in AMD. Availability of patient specific models which can generate large numbers of RPE cells would provide a significant advance for a better understanding of AMD physiopathology, the contribution of environmental, lifestyle and dietary factors and drug testing. The advent of iPSC technology has made the *in vitro* modelling of many inherited diseases possible; however to date this method has predominantly been viewed as useful to physiopathologies that manifest early during development or in childhood. Three recent studies have implemented premature aging approaches to model Parkinson’s disease (52) and AMD (23) using iPSC, paving the way for modelling of complex age related disease.

In this manuscript, we investigated whether iPSC could be used to provide a disease modelling tool which mimics an AMD phenotype in the laboratory in the absence and presence of stress stimuli. Our rationale was to focus on patients phenotyped with a significant risk factor for AMD, such as Y402H polymorphism in the *CFH* gene. Using the iPSC derived RPE cells generated from low and high risk donors in the absence of any stress stimuli, we have been able to confirm several key cellular features of AMD as follows: *(i)* increased expression of inflammatory markers (for example *IL1β*); *(ii)* lower expression of the protective oxidative stress markers (*SOD2*); *(iii)* increased number of stress vacuoles (and their surface area); *(iv)* increased accumulation of lipid droplets and *(v)* increased expression of LC3 vesicles and higher p62 expression/aggregate suggestive of impaired autophagy. Most importantly, we were able to identify the formation of deposits comprising of components including Apolipoprotein E and C5b-9, in keeping with drusen formation. These deposits occupied a significantly higher volume in the RPE derived from high-risk lines. The presence of drusen and its larger volume in RPE derived from the high risk iPSC lines, together with confirmation of key molecular features observed in previous AMD studies,
suggest that this iPSC model closely mimics the disease phenotype observed in AMD patients.

The complement proteins associated with AMD (FH, F1, FHR1, FHR3, C2, C3) are plasma proteins predominantly produced in the liver; however biosynthesis at extrahepatic sites is now well recognised (17, 18). As with the blood-brain barrier, the blood-retinal barrier limits access to circulating plasma proteins and it has been suggested that local complement synthesis may be required for its effects in such areas. Indeed, it has been shown that choroid and RPE as well as cultured unstimulated RPE cells produce transcripts for most classical (CP) and alternative (AP) pathway complement genes (17, 18). Data summarised in this manuscript indicate that iPSC derived RPE cells express the active complement proteins and are able to modulate their expression in response to stress stimuli without having to rely on secretion from the choroid and diffusion through the BrM as previously suggested (18).

In view of this local complement regulation by RPE cells themselves, we were interested to assess the response of low and high risk RPE responses to stress stimuli. Since a trend towards an association between severity of light exposure and AMD has been suggested by epidemiological studies, we exposed the iPSC-derived RPE to repeated doses of UV for five consecutive days. Pigmentation level between the two groups was not significantly different. The low risk RPE cells responded by increasing the expression of inflammatory marker IL6 and complement factor I (CFI). More significant changes were observed in high risk RPE cells, which upregulated the expression of protective oxidative stress defence protein, SOD2 as well as complement factor H (CFH) and its truncated form, FHL-1, in addition to showing an improved ultrastructural (increased microvilli length, reduced number of stress vacuoles and lower mitochondrial area) and functional (lower volume of drüsen like deposits) properties. These results indicate that the low and high-risk AMD-RPE cells respond very differently to UV exposure and moreover this provides evidence for UV mediated functional
and cellular improvement of AMD-associated cellular changes in high-risk AMD-RPE cells. These intriguing results which we attribute to increased SOD2 expression need to be validated in a larger number of cell lines derived from additional high risk donors over longer intervals and with different UV doses. They do however highlight an important role for increased oxidative stress defence as a potential therapeutic strategy for AMD, corroborating recent data obtained with the HTRA1/ARMS2-iPSC model and exposure to nicotinamide (25).

Several clinical trials attempting to inhibit the complement pathway have been completed or are under way including FCFD4514S (anti-CFD [complement factor D]), LFG 316 (anti-C5), ARC1905 (anti-C5), catalyst protease (anti-C3) and eculizimab (anti-C5) (53, 54). In particular, Lampalizumab (FCFD4514S) has been shown to reduce the geographic atrophy (GA) enlargement in phase II trials of dry AMD in patients who also have a complement factor I (CFI) polymorphism, indicating that inhibition of complement is a promising approach. Nonetheless, human clinical trials are complex, expensive and require prolonged periods to assess the long-term effect of a therapy in large numbers of patients with specific phenotypes to provide a consistent end point. The assessment is further complicated by differing progression rates in patients and the uncertain choice of disease endpoints to assess progression (55). This is a significant problem and can lead to trials having negative but disputed conclusions (e.g. the COMPLETE study on Eculizimab for dry AMD) (56). A robust and well characterised in vitro model such as the one described herein provides an efficient tool to assess potential therapeutic agents to treat AMD (such as complement pathway modulation), to better understand disease physiopathology and to test/repurpose drugs.
Materials and methods

Human donors

Written informed consent was obtained from each donor, all samples were obtained as part of a NHS research ethics committee approved biobank for fibroblasts from patients with retinal disease (ethics number 11/NE/0294) and based at the Institute of Genetic Medicine, Newcastle University and adhered to the tenets set forth in the Declaration of Helsinki.

iPSC generation

Dermal fibroblasts were isolated from skin biopsies taken from patients with wet AMD and age matched donors with no clinical or genotypic indication of ocular disease (Supplementary figure 1, A and B). iPSCs were generated by Sendai viral transduction of the transcription factors OCT4, SOX2, KLF4, and c-MYC (Thermo Fisher, CytoTune2-iPS Reprogramming Kit, Waltham, Massachusetts, USA) following manufacturer’s instructions. iPSCs were maintained in defined conditions in mTeSR1 (Stem Cell technologies, Vancouver, Canada) on growth factor reduced Matrigel (BD Biosciences, San Jose, USA).

iPSC characterisation

The pluripotency of iPSC lines was confirmed with immuno-fluorescence, flow cytometry and RT-PCR. Cells were fixed with 4% paraformaldehyde for 15 minutes and stained with primary antibodies OCT4 and SSEA4 (Abcam, UK). Primary antibodies were detected using Alexa Fluor secondary antibodies (Supplementary figure 4, B). Nuclei were stained using 4’,6-diamidino-2-phenylindole (DAPI). Images were captured using a fluorescence microscope (Leica Axiovert, Germany). iPSC were assessed for their propensity to generate all three germ layers using primary antibodies against AFP, TUJ1 and SMA, primary antibodies were detected using Alexa Fluor secondary antibodies (3-Germ Layer Immunocytochemistry Kit Invitrogen, USA). RT-PCR, was used to detect mRNA transcripts of key pluripotency transcription factors, NANOG, KLF4, c-MYC & SOX2 (Supplementary
figure 4, C) and Sendai clearance (Supplementary figure 5, A). RNA was isolated from each iPSC line, RNA was isolated using a column biased method (Promega, USA) and one thousand ng of total RNA was reverse transcribed (GoScript Reverse Transcription System, Promega, USA). Standard RT-PCR was performed and PCR products electrophoresed on a 2% agarose gel.

Directly conjugated antibodies against NANOG (Cell Signalling, USA) and TRA-1-60 (Millipore, UK) (Supplementary figure 4, B) were used detect the percentage population of pluripotent cells using BD FACS Canto II (BD Biosciences, San Jose, USA).

Karyotyping

All cell lines were karyotyped using Illumina CytoSNP analysis and the BlueFuse Multi 4.3 software (Illumina, San Diego, United States) according to standard protocols of the manufacturer.

Generation of iPSC-RPE

iPSC were allowed to reach one hundred percent confluency, at which point the medium was switched from mTeSR1 to RPE differentiation medium (AdRPMS, Thermo Fisher Scientific, B-27® Supplement (Thermo Fisher Scientific), 10% Knock-Out Serum Replacement (Thermo Fisher Scientific), 1% 100 X GlutaMAX (Thermo Fisher Scientific), and 1% Penicillin-Streptomycin Solution (Thermo Fisher Scientific). Cells were cultured for 16 days with medium replenished daily for the first 14 days. On day 16 the differentiation medium was supplemented with 2 µM Purmorphamine (Stemcell technologies, Vancouver, Canada) until day 21. Medium was replenished twice a week for the next 3-4 months. RPE patches were mechanically picked and placed in TryPLE (10X) (Invitrogen, USA) for 30 minutes to dissociate the cells, agitated by gentle pipetting at 10, 20 and 30 minutes. Cells were sieved using a 100µm cell strainer and re-plated at 4.5x 10⁵ cells per cm² on 24 well plates or 0.33 cm² PET hanging cell culture inserts (Merck Millipore; Billerica, United States) coated with PLO/laminin (50ng/µl) (Sigma-Aldrich, USA).
**Western Blotting**

Supernatant was collected from apical portion of RPE cultures grown on transwell inserts incubated with DMEM/F12 for 4 days, soluble proteins were resolved on BioRad® 4–20% Tris-Glycine pre-cast gels non-reduced (Bio-Rad, USA) and transferred to Nitrocellulose Pre-Cut Blotting Membranes (Thermo Fisher, USA). Blocking and antibody incubations were performed using 2% milk solutions. Membranes were incubated with primary antibody at 4°C overnight with gentle agitation. Primary antibodies were detected using applicable horseradish peroxidase (HRP) - conjugated secondary antibodies (Supplementary Figure 4, B). Detection of HRP-labelled secondary antibody was performed with ECL SuperSignal Substrate (Pierce Biotechnology, USA). Bands were identified by autoradiography with Carestream Kodak Biomax XAR film (Sigma-Aldrich, USA) and developed.

**DNA extraction and sequencing**

DNA was extracted using a column biased method (Qiagen, Germany), sequence tagged PCR was performed using 100ng of DNA. Sanger sequencing was performed (GATC biotech, Germany) and results were interpreted using finch TV (Geospiza, USA).

**Quantitative RT-PCR**

RNA was extracted from frozen cell pellets using ReliaPrep™ RNA Cell Miniprep System as per the manufactures instructions. RNA quantification was performed with a NanoDrop™2000 spectrophotometer (Thermo, USA). We ensured that the 260/280 ratio and concentration was between 1.7–2.1 and yields of >250ng/μl respectively. cDNA synthesis was performed using Promega GoScript™ Reverse Transcription System as per the manufactures instructions. All experiments were performed using a QuantStudio™ 7 Flex Real-Time PCR System (Applied Biosystems, UK), using SYBR green reaction technology (Promega, UK). Cycle parameters are as follows: 40 cycles of 95°C for 15 seconds and 60°C for 1 minute, finalising with a Melt Curve Stage. The Livak method (ΔΔCt) was used (57), Ct results of the target genes were normalised to the Ct of the reference gene GAPDH.
(ΔC_t), the ΔC_t obtained then normalised to the ΔC_t of the calibrator, yielding the (ΔΔC_t), finally the fold difference in expression was determined (2^{ΔΔC_t}). A list of the primers used can be found in (Supplementary figure 5, B).

**RNA Sequencing**

RNA was extracted using RNeasy Micro Kit (Qiagen)) according to the manufactures instructions, from six cell culture inserts, three of each genotype. cDNA was generated using SMART-Seq v4 Ultra Low Input RNA Kit (Clontech, USA). Sequencing was carried out on a NextSeq 500 (Illumina). 75 bp paired-end sequencing was carried out using a NextSeq 500 High Output v2 Kit (150 cycles) (Illumina). RNA-seq data were processed and analysed to identify differentially expressed RNA. The quality of sequencing reads was firstly checked with FastQC (Version 0.11.2) (58). Poly-N tails were trimmed off from reads with an in house Perl script. Low quality bases (Q < 30) and standard Illumina (Illumina, Inc. California, U.S.) paired-end sequencing adaptors on 3’ ends of reads were trimmed off using autoadapt (Version 0.2) and only those that were at least 20bp in length after trimming were kept. The high quality reads were then mapped to the human reference genome hg38 with STAR (Version 2.5.0c) (59). Reads mapped to genes were then counted with HTSeq-count (Version 0.6.1) (60) according to annotations from GENCODE (Version 24) (61). Differentially expressed genes were identified with Bionconductor (Version 3.2) package DESeq2 (Version 1.10.1) (62). Genes differentially expressed in the 99.73 percentile, whereby genes that lie three standard deviations from the mean (µ- 3σ) were selected (≥5 fold change). This gene list was queried against the PANTHER (protein annotation through evolutionary relationship) classification system to highlight disproportionally expressed pathways. RNA-seq data is deposited into GEO (accession number GSE91087). A list of the overrepresented glycogenesis genes can be found in Table 6.

**Pigment Bleaching**
Post fixation and prior to immunocytochemistry, RPE cells were bleached using a Melanin Bleach Kit (Polysciences, USA) to remove pigmentation, as melanosomes can cause excessive auto-fluorescence. Pre-treatment Solution A was added for 5 minutes at room temperature, the solution was removed and cells washed two times with PBS. Pre-treatment Solution B was then added for 1-3 minutes until pigmentation was removed. This solution was removed and cells washed again with PBS.

**Phagocytosis of rod outer segments**

Bovine POS were obtained from InVision BioResources (Seattle, United States). Prior to performing the assay, POS were FITC labelled using the following procedure. The POS were centrifuged at 4500 $\times$ g for 4 minutes. They were then re-suspended in AdRPMI, 10% FBS with 0.4 mg/ml FITC (Sigma) and incubated for 1 hour at room temperature protected from light. This was followed by another centrifugation for 4 minutes at 4500 $\times$ g. POS were washed three times with PBS and then re-suspended in 2.5% sucrose (Sigma) in PBS and stored in -80°C until further use. For phagocytosis experiments, normal RPE cell medium was changed to the POS medium (AdRPMI, B27, 10% FBS). Once thawed, POS were re-suspended in POS medium. $1 \times 10^6$ FITC-labelled POS were added per cell culture insert for 4 hours at 37°C. In parallel negative control experiments were performed where cells were kept for the same duration but at 4°C. The incubations were followed by two cell washes with PBS. Cells were then dissociated with TrypLE™ Select Enzyme (10X) (Thermo Fisher Scientific) and washed. They were then re-suspended in 2% FBS solution in PBS with the addition of DRAQ5 (1:400, BioStatus; Shepshed, United Kingdom) for 5 minutes. Extracellular fluorescence was quenched with 0.2% Trypan Blue Stain (Thermo Fisher Scientific) for 10 minutes. Cells were then washed at least three times with PBS and re-suspended in 2% FBS solution in PBS. Cells were analysed on a BD™ LSR II flow cytometer (BD Biosciences; Franklin Lakes, United States), collecting at least 10,000 events.
per sample. The data was analysed on BD FACSDiva software (BD Biosciences), % = \left( \frac{F I T C \, p o s i t i v e}{T o t a l \, n u m b e r \, o f \, c e l l s} \right) \times 100.

**Immunofluorescence**

Cells were washed once with PBS, followed by fixation with 4% paraformaldehyde for 15 minutes at room temperature. Cells were then washed once with PBS, followed by blocking in 0.25% Triton-X-100 (Sigma) and 5% NGS (Thermo Scientific) in PBS for 1 hour. This solution was removed and replaced with antibody diluent (0.25% Triton-X-100, 1% BSA in PBS) with applicable antibody dilution; [Anti-ZO1, rabbit (Invitrogen; dilution 1:200), Anti-C5b-9 (Dako 1:200), Anti-APOE (Merck Millipore 1:1000), Anti-LC3 (Cell Signalling 1:250), Anti-p62 (1:500)] (Supplementary Figure 4, B) at 4°C overnight. Cells were washed 3 times in PBS followed by incubation with secondary antibodies [Cy™3 AffiniPure Goat Anti-Rabbit IgG (Jackson ImmunoResearch (West Grove, United States); dilution 1:1000), Anti-mouse IgG–FITC antibody (Sigma; dilution 1:1000) Donkey anti-Goat 488 (1:500, Abcam) Donkey anti mouse 647 (Abcam 1:500)] for 1 hour at room temperature. Cells were washed as stated previously and mounted in Vecta sheild (Vector Labs, USA) with Hoechst 33342 (1:1000, Thermo Scientific), TO-PRO-3 (1:1000, Thermo Scientific) or DAPI (Sysmex, 1:1000). C5b-9 and APOE signals were detected using a Nikon A1R confocal (resonant, invert) (Nikon, Japan), 45-50µm optimally sampled. Image processing was performed using Huygens Essential (Germany) co-localisation with the threshold set to 1%

**In vitro and in vivo 3 germ layer differentiation**

**In vitro:** iPSCs were spontaneously differentiated to allow the emergence of cell types representative of the three embryonic germ layers. iPSCs were allowed to reach 80% confluency after which the media was switched to DMEM/F12 (Thermo Fisher Scientific), 20% Foetal bovine serum (FBS) (Thermo Fisher Scientific), 1% Penicillin–Streptomycin Solution (Thermo Fisher Scientific) and 1% MEM Non-essential Amino Acids Solution (Thermo Fisher Scientific). Medium was replaced daily for 3 weeks. 3-Germ Layer Immunocytochemistry Kit
(Thermo Fisher Scientific) was used to detect cells positive for markers of Mesoderm, Endoderm and Ectoderm. Briefly, media was removed from cellular monolayers, followed by a 15 minute incubation with fixative solution. Fixative was removed and Permeabilisation Solution was added for 15 minutes, this was then removed and replaced with blocking solution for 1 hour, after which the applicable antibody was added; Smooth muscle actin (SMA) (Mesoderm), alpha-fetoprotein (AFP) (endoderm) or Anti-beta III Tubulin (TUJI1) (Ectoderm). Cells were washed 3 times for 3 minutes in wash buffer. Secondary antibody was then added (Supplementary Figure 4, B), for 1 hour, after which the cells were washed as previously stated and 1–2 drops/mL of NucBlue was added. Plates were stored at 4°C prior to imaging on a Zeiss Axioplan microscope. All incubations occurred at room temperature unless otherwise stated.

Teratoma formation in immuno-deficient mice

All procedures were approved and conformed to institutional guidelines. 1x10⁶ iPSCs were injected subcutaneously into the right flank of adult NOD/SCID mice. All cells were co-transplanted in a 50µl Matrigel carrier, (BD Biosciences) to enhance teratoma formation. Mice were sacrificed after 70-90 days, and teratoma tissues extracted. Teratoma material for histological analysis was fixed in Bouins fixative [70% saturated picric acid (Sigma); 25% formaldehyde (37%/40%, Sigma); 5% glacial acetic acid (Sigma)] overnight. Tissues were processed then sectioned to 6μm then counterstained with either Haematoxylin and Eosin or Massons trichrome stain. Sections were assessed using bright field microscopy on an Axio Imager (Lecia, Germany).

Trans-epithelial resistance

Trans-epithelial resistance (TER) was measured with a Millicell ERS-2 Voltohmmeter (Merck Millipore). Firstly the electrical resistance of a blank cell culture insert with media in both apical and basal compartments was measured, after which inserts with cells were measured.
A minimum of two repeated measurements were made of each insert. TER was calculated using the following formula: \[ \text{TER (Ωcm}^2\) = \left(\frac{\text{Average Blank}}{\text{Average Sample}}\right) \times \text{Area}. \]

**Transmission electron microscopy**

Cells were fixed with 2% glutaraldehyde and kept at 4°C. TEM including all the cell processing was performed at Newcastle University Electron Microscopy Research Services. Ultrathin sections were stained with heavy metal salts (uranyl acetate and lead citrate) and imaged on a Philips CM100 TEM.

**Statistical analysis**

Shapiro-Wilk test was used to determine normality, for normally distributed data sets, one-way ANOVA followed by Tukey’s post-hoc test was used to analyse intergroup differences between samples. Two-way ANOVA was used to compare between samples and treatment groups. For non-normally distributed data Wilcoxon matched-pairs signed rank test was utilised in matched samples, while Mann Whitney test were used all other times. GraphPad Prism 7.0 (San Diego, USA) was used to perform all statistical analyses. Data are presented as mean ± S.D. and a confidence interval of 95% was set and p ≤0.05 was considered statistically significant.

**Funding**

This work was funded by the Macular Society UK, European Research Council [614620], BBSRC (#BB/I020209/1), IMI2 funded EbiSC project and Bayer AG.

**Author contributions and Acknowledgements**

**D.H,** experimental design, analysed data, performed research and prepared manuscript, **J.C,** fund raising, experimental design and performed research **S.B,** performed research, **V.C,** performed research, **A.B,** performed research, **L.L,** performed research, **G.O,** performed research, **G.A,** performed research, **C.M,** fund raising and experimental design, **Y.X,**
analysed data, S.P, performed research, analysed data and contributed to manuscript writing. S.A, performed research and analysed data, V.K, experimental design, performed research and data analysis, A.L, experimental design and fund raising, G.S, experimental design and performed research, M.M experimental design and fund raising, D.S, experimental design and fund raising, L.A, designed research and fund raising, D.K, experimental design and fund raising M.L designed and performed research, prepared manuscript and fund raising. All authors contributed to the final approval of manuscript.

Special thanks to Ms Tracey Davey and Dr Kathryn White at Newcastle University Electron Microscopy Research Services for sample preparation and assistance with TEM image processing, flow cytometry core facility for help with flow cytometric analysis, Dr. Angela Pyle for carrying out mitochondrial deletion analysis and Dr. Heli Skottman for help with TER analysis.

References

1. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye. 2010;24(11):1692-9.
2. Bressler NM, Bressler SB, Congdon NG, Ferris FL, 3rd, Friedman DS, Klein R, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003;121(11):1621-4.
3. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Brit J Ophthalmol. 2003;87(3):312-7.
4. Wang JJ, Mitchell P, Smith W, Cumming RG. Bilateral involvement by age related maculopathy lesions in a population. Brit J Ophthalmol. 1998;82(7):743-7.
5. Crump F. Society urgently calls for more funding into macular research https://www.macularsociety.org/: Macular Society; 2016 [updated 28/09/2016; cited 2016 28/09/2016]. Available from: https://www.macularsociety.org/.
6. Gonzales CR, Adamis AP, Cunningham ET, D'Amico DJ, Goldbaum M, Guyer DR, et al. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis. Retina-J Ret Vit Dis. 2005;25(7):815-27.
7. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Asses. 2008;12(16):1-+.  
8. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. Ophthalmology. 2009;116(1):57-65.  
9. Nowak JZ. Age-related macular degeneration, an incurable ophthalmological disease - unraveling a complex pathogenesis and searching satisfying therapies. Pharmacol Rep. 2010;62:113-4.  
10. Gorin MB. Genetic insights into age-related macular degeneration: Controversies addressing risk, causality, and therapeutics. Mol Aspects Med. 2012;33(4):467-86.  
11. Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nature genetics. 2016;48(2):134-43.  
12. Holliday EG, Smith AV, Cornes BK, Buitendijk GHS, Jensen RA, Sim XL, et al. Insights into the Genetic Architecture of Early Stage Age-Related Macular Degeneration: A Genome-Wide Association Study Meta-Analysis. PLoS one. 2013;8(1).  
13. Grassmann F, Fritsche LG, Keilhauer CN, Heid IM, Weber BHF. Modelling the Genetic Risk in Age-Related Macular Degeneration. PLoS one. 2012;7(5).  
14. Crabb JW, Miyagi M, Gu XR, Shadrach K, West KA, Sakaguchi H, et al. Drusen proteome analysis: An approach to the etiology of age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(23):14682-7.  
15. Mullins RE, Johnson MN, Faidley EA, Skeie JM, Huang JA. Choriocapillaris Vascular Dropout Related to Density of Drusen in Human Eyes with Early Age-Related Macular Degeneration. Invest Ophth Vis Sci. 2011;52(3):1606-12.  
16. Seth A, Cui J, To E, Kwee M, Matsubara J. Complement-associated deposits in the human retina. Invest Ophth Vis Sci. 2008;49(2):743-50.  
17. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, et al. The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited. Progress in retinal and eye research. 2010;29(2):95-112.  
18. Clark SJ, Ridge LA, Herbert AP, Hakobyan S, Mulloy B, Lennon R, et al. Tissue-Specific Host Recognition by Complement Factor H Is Mediated by Differential Activities of Its Glycosaminoglycan-Binding Regions. Journal of Immunology. 2013;190(5):2049-57.  
19. Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN, et al. Impaired Binding of the Age-related Macular Degeneration-associated Complement Factor H 402H
20. Keenan TDL, Pickford CE, Holley RJ, Clark SJ, Lin WC, Dowsey AW, et al. Age-Dependent Changes in Heparan Sulfate in Human Bruch's Membrane: Implications for Age-Related Macular Degeneration. Invest Ophth Vis Sci. 2014;55(8):5370-9.
21. Toomey CB, Kelly U, Saban DR, Rickman CB. Regulation of age-related macular degeneration-like pathology by complement factor H. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(23):E3040-E9.
22. Tolentino MJ, Dennrick A, John E, Tolentino MS. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration. Expert Opin Inv Drug. 2015;24(2):183-99.
23. Yang J, Li Y, Chan L, Tsai YT, Wu WH, Nguyen HV, et al. Validation of genome-wide association study (GWAS)-identified disease risk alleles with patient-specific stem cell lines. Human molecular genetics. 2014;23(13):3445-55.
24. Stojkovic M, Lako M, Stojkovic P, Stewart R, Przyborski S, Armstrong L, et al. Derivation of human embryonic stem cells from day-8 blastocysts recovered after three-step in vitro culture. Stem cells. 2004;22(5):790-7.
25. Saini JS, Corneo B, Miller JD, Kiehl TR, Wang Q, Boles NC, et al. Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration. Cell stem cell. 2017.
26. Chong EW, Islam FMA, Robman LD, Aung KZ, Richardson AJ, Baird PN, et al. Age-Related Macular Degeneration Phenotypes Associated with Mutually Exclusive Homozygous Risk Variants in Cfh and Htra1 Genes. Retina-J Ret Vit Dis. 2015;35(5):989-98.
27. Kanemura H, Go MJ, Nishishita N, Sakai N, Kamao H, Sato Y, et al. Pigment epithelium-derived factor secreted from retinal pigment epithelium facilitates apoptotic cell death of iPSC. Scientific reports. 2013;3:2334.
28. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(20):7227-32.
29. Mandal NA, Ayyagari R. Complement factor H: Spatial and temporal expression and localization in the eye. Invest Ophth Vis Sci. 2006;47(9):4091-7.
30. Justilien V, Pang JJ, Renganathan K, Zhan X, Crabb JW, Kim SR, et al. SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci. 2007;48(10):4407-20.
31. Mathis T, Housset M, Eandi C, Beguier F, Touhami S, Reichman S, et al. Activated monocytes resist elimination by retinal pigment epithelium and downregulate their OTX2 expression via TNF-alpha. Aging cell. 2016.
32. Doyle SL, Ozaki E, Brennan K, Humphries MM, Mulfaul K, Keaney J, et al. IL-18 Attenuates Experimental Choroidal Neovascularization as a Potential Therapy for Wet Age-Related Macular Degeneration. Sci Transl Med. 2014;6(230).

33. Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol. 2013;13(6):438-51.

34. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol. 2005;123(6):774-82.

35. Schang AL, Bleux C, Chenut MC, Ngo-Muller V, Querat B, Jeanny JC, et al. Identification and analysis of two novel sites of rat GnRH receptor gene promoter activity: the pineal gland and retina. Neuroendocrinology. 2013;97(2):115-31.

36. Wang SZ, Yan RT. The Retinal Pigment Epithelium: a Convenient Source of New Photoreceptor cells? Journal of ophthalmic & vision research. 2014;9(1):83-93.

37. Yan RT, Li X, Wang SZ. Photoreceptor-like cells in transgenic mouse eye. Invest Ophthalmol Vis Sci. 2013;54(7):4766-75.

38. Radeke MJ, Radeke CM, Shih YH, Hu J, Bok D, Johnson LV, et al. Restoration of mesenchymal retinal pigmented epithelial cells by TGF beta pathway inhibitors: implications for age-related macular degeneration. Genome Med. 2015;7.

39. Narimatsu T, Ozawa Y, Miyake S, Kubota S, Hirasawa M, Nagai N, et al. Disruption of Cell-Cell Junctions and Induction of Pathological Cytokines in the Retinal Pigment Epithelium of Light-Exposed Mice. Invest Ophth Vis Sci. 2013;54(7):4555-62.

40. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC bioinformatics. 2013;14:128.

41. Clark SJ, Schmidt CQ, White AM, Hakobyan S, Morgan BP, Bishop PN. Identification of Factor H-like Protein 1 as the Predominant Complement Regulator in Bruch's Membrane: Implications for Age-Related Macular Degeneration. Journal of Immunology. 2014;193(10):4962-70.

42. Handa JT, Verzijl N, Matsunaga H, Aotaki-Keen A, Lutty GA, te Koppele JM, et al. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Invest Ophthalmol Vis Sci. 1999;40(3):775-9.

43. Wang L, Clark ME, Crossman DK, Kojima K, Messinger JD, Mobley JA, et al. Abundant lipid and protein components of drusen. PloS one. 2010;5(4):e10329.

44. Lee HC, Yin PH, Lu CY, Chi CW, Wei YH. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. Biochem J. 2000;348:425-32.
45. Mitter SK, Song CJ, Qi XP, Mao HY, Rao H, Akin D, et al. Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD. Autophagy. 2014;10(11):1989-2005.
46. Jarrett SG, Boulton ME. Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med. 2012;33(4):399-417.
47. Whitehead AJ, Mares JA, Danis RP. Macular pigment: a review of current knowledge. Arch Ophthalmol. 2006;124(7):1038-45.
48. Sparrow JR, Zhou J, Ben-Shabat S, Vollmer H, Itagaki Y, Nakanishi K. Involvement of oxidative mechanisms in blue-light-induced damage to A2E-laden RPE. Invest Ophth Vis Sci. 2002;43(4):1222-7.
49. Delapaz MA, Anderson RE. Lipid-Peroxidation in Rod Outer Segments - Role of Hydroxyl Radical and Lipid Hydroperoxides. Invest Ophth Vis Sci. 1992;33(7):2091-6.
50. Jonas JB, Tao Y, Neumaier M, Findeisen P. Cytokine concentration in aqueous humour of eyes with exudative age-related macular degeneration. Acta Ophthalmol. 2012;90(5):e381-e8.
51. Yu W, Naim JO, McGowan M, Ippolito K, Lanzafame RJ. Photomodulation of oxidative metabolism and electron chain enzymes in rat liver mitochondria. Photochemistry and photobiology. 1997;66(6):866-71.
52. Miller JD, Ganat YM, Kishinevsky S, Bowman RL, Liu B, Tu EY, et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell stem cell. 2013;13(6):691-705.
53. Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clinical & experimental ophthalmology. 2012;40(1):18-26.
54. Schaal KB, Rosenfeld PJ, Gregori G, Yehoshua Z, Feuer WJ. Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration. Ophthalmology. 2016;123(5):1060-79.
55. Chandramohan A, Stinnett SS, Petrowski JT, Schuman SG, Toth CA, Cousins SW, et al. Visual Function Measures in Early and Intermediate Age-Related Macular Degeneration. Retina-J Ret Vit Dis. 2016;36(5):1021-31.
56. Yehoshua Z, Garcia CAA, Nunes RP, Gregori G, Penha FM, Moshfeghi AA, et al. Systemic Complement Inhibition with Eculizumab for Geographic Atrophy in Age-Related Macular Degeneration. Ophthalmology. 2014;121(3):693-701.
57. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods. 2001;25(4):402-8.
58. Andrews S. FastQC A Quality Control tool for High Throughput Sequence Data Available from: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
Figure Legends

Figure 1. Derivation of AMD-iPSC RPE. (A) Light microscopy images of iPSC-RPE cells derived from low risk donors [F018 and F116:402Y] donor, and high risk AMD patients [F180 and F181:402H]. Scale bar = 50 µm. (B) Flatbed scanned images of a representative well from 6 well plates, pigmented patches are clearly visible. Scale bar = 17.4 mm. (C) CRALBP/ ZO-1 and BEST1 immunostaining of representative iPSC-derived RPE cells, Scale = 25 µm. (D) Immunofluorescence representative images of iPSC-RPE and orthogonal images along X and Y axis (Green = Na⁺ K⁺-ATPase) (Blue = DAPI) Scale bar = 50 µm, A=apical, B=basal. (E) Pigment Epithelium-Derived Factor (PEDF) ELISA of apical and basal supernatant, concentration ng/ml. (F) Trans-epithelial Resistance (TER) data shown as Ωcm² (resistance).

Figure 2. Expression and secretion of complement proteins by iPSC-RPE by western blotting. (A) Western blot of protein excreted into the medium by RPE cells, Anti-FH ab shows a band visible at 150 kDa and FHL-1 visible at 37 kDa. (B) Anti-FI ab indicates a band at 65 kDa. (C) C3 is visible at 187 kDa, while C3b is also visible in the positive control at 90 kDa. (D) Western blot of a fluid phase tripartite co-factor assay probed with anti-C3 Ab. Supernatant from AMD patient iPSC-RPE cells cultured for 48 hrs in serum free media was incubated with purified C3b to test the activity of FI and FH previously demonstrated to be
secreted by these cells (A,B) (lane 6). Activity was confirmed by the generation of a 67-kDa α’1 chain and a 40-kDa α’2 chain. It is also observed that these cells had secreted C3 into the supernatant (C) (lane 5). The serum free media alone had no effect on C3 (lane 4). C3b/FH combined had minimal cleavage (lane 1) and C3b alone was not cleaved (lane 2). C3b/FH/FI combined were able to cleave C3b to the 67-kDa α’1 chain and a 40-kDa α’2 chain in the positive control (lane3).

**Figure 3.** Gene expression analysis in low and high risk AMD iPSC-RPE. Data is presented as mean +/- SEM, n=3.

**Figure 4.** Drüsen like deposits form in high risk iPSC-RPE. (A) Volume of APOE and C5b-9 co-expressing deposits in low and high risk iPSC-RPE, dashed black line represents clinically significant drüsen size. High risk donor iPSC-RPE cells accumulate larger deposits than low risk, n=3. (B) Low risk iPSC-RPE example of F116, Blue = DAPI, Red = C5b-9 and Green = APOE. Scale bar = 50 µm. (C) High risk iPSC-RPE example of F181, Blue = DAPI, Red = C5b-9 and Green = APOE. Scale bar = 50 µm. (D) Secondary antibody only control, Blue = DAPI, Red = C5b-9 and Green = APOE. Scale bar = 50 µm. (E) Oil red O staining, high risk donor iPSC-RPE contained larger lipid globules than low risk donors. (F) Examples of low and high risk donor Oil red O staining. Scale bar = 200 µm.

**Figure 5.** High risk iPSC-RPE show ultrastructural changes in TEM analysis. (A) Microvilli length (calculated per field of view: 100 µm²) is decreased in high risk donor iPSC-RPE, n=3. (B) Mitochondrial area (calculated per field of view: 100 µm²) was increased in high risk donor iPSC-RPE, p=0.0417, n=3. (C) Mitochondrial number (calculated per field of view: 100 µm²) was decreased in high risk donor iPSC-RPE, p=0.0008, n=3. (D) The number of vacuole structures (calculated per field of view: 100 µm²) was greatly increased in high risk donor iPSC-RPE, p=0.0055, n=3. (E) Example of low risk iPSC-RPE cells, left hand side = F018, right hand side = F116, Scale bar = 2 µm. (F) Example of high risk iPSC-RPE cells,
left hand side = F180, right hand side = F181, Red Asterisk indicate vacuoles. Scale bar = 2 µm.

Figure 6. Autophagy is blocked in high risk iPSC-RPE cells but not in high risk dermal fibroblasts. (A) Example fluorescence staining of low risk fibroblasts Blue = DAPI, Green = LC3 and Red = p62. Scale bar = 10 µm. (B) Example fluorescence staining of high risk fibroblasts Blue = DAPI, Green = LC3 and Red = p62. Scale bar = 10 µm. (C) The number of LC3 vesicles per cell did not differ between genotypes in iPSC-RPE cells. (D) Number of p62 positive aggregates per cell was not affected by genotype (E). The intensity of p62 decreases in high risk AMD iPSC-RPE cells. (F) Example fluorescence staining of low risk iPSC-RPE Blue = TO-PRO-3, Green = LC3 and Red = p62. Scale bar = 10 µm. (G) Example fluorescence staining of high risk iPSC-RPE Blue = TO-PRO-3, Green = LC3 and Red = p62. Scale bar = 10 µm. (H) LC3 aggregates were significantly increased in high risk iPSC-RPE (I) p62 aggregates per cell were significantly increased in high risk (J) p62 intensity also increased.

Figure 7. The response of low and high risk RPE to intermittent UV exposure. (A-N) Quantitative RT-PCR expression data shown as fold change in relation to low risk control, data are presented as mean +/- SEM, n=3, * p< 0.5. (O) Average length of microvilli per field of view (100 µm²), UV exposure increased microvilli length in high risk iPSC-RPE cells, p<0.0001. (P) Average mitochondrial area per field of view (100 µm²), UV exposure decreased mitochondrial area in both low and high risk iPSC-RPE (p=0.0003 & p=0.0002). (Q) Average mitochondrial number per field of view (100 µm²), UV exposure did not influence the average number of mitochondria (p=0.9789). (R) Average vacuole number (calculated per field of view: 100 µm²), UV exposure decreased the number of vacuoles in high risk cells, p=0.0038. (S) “Drüsen” area, UV exposure decreased the deposition of C5b-9 and APOE in high risk iPSC-RPE cells, * p=0.0002.
**Supplementary Figure 1**

(A) Table showing donor ID age and gender and Sanger sequencing reads of rs1061170, rs11200638, rs10490924. (B) Spectral domain optical coherence tomography (OCT) and infrared fundal images of homozygous Y402H AMD Donors. Both patients had unilateral wet AMD in the left eye (C and C) and reticular drüsen in their fellow eyes (B’ and C’). OCTs show retinal pigment epithelial detachment and choroidal neovascularisation (*), subretinal fluid (+) and intraretinal fluid (arrow) in the eyes affected by wet AMD. The reticular drüsen are seen as a stippled appearance on the infrared images in the macular areas of the fellow eyes.

**Supplementary figure 2**

(A) Immunofluorescence of high and low risk iPSC, Green = OCT4, Red = SSEA4 and Blue = DAPI. Scale bar = 200 µm. (B) RT-PCR of all iPSC lines compared to H9 cells. NANOg, KLF4, c-MYC and SOX2 were tested. GAPDH and RLP13A were controls. (C) Example of flow cytometry of iPSC line F180, showing TRA-1-60 and NANOg, populations consisted of over 85% dual positive cells in all lines tested. (D) Immunocytochemistry showing the presence of three germ layers from in vitro differentiation of iPSC. A representative example from a high risk AMD-iPSC is shown. Scale bar = 200 µm. (E) Teratoma staining, cartilage was stained with Weigerts iron Haematoxylin, Nuclei- brown-black, Cartilage- pale blue, and Cytoplasm- pink. Mayers’ Haematoxylin (Haemalum) and Eosin was used for all other staining. (F) Sendai clearance, polycystronic primers spanning Sendai genome and transcription factor were used to detect absence of residue viral induction elements. (G) CytoSNP, 70,000 SNPs from across the genome were compared in iPSC against parent fibroblasts to determine any chromosomal alterations.

**Supplementary figure 3**
(A) RT-PCR of CFH and FHL-1 in iPSCs. (B) Enrichr results queried against OMIM disease database. (C) RNA sequencing result of downregulated and upregulated genes residing in the 0.3% percentile and 99.7% percentile were selected, equating to -5.532 fold change or greater and 5.66 or greater respectfully. Gene list shown ranked in order of highest to lowest expressed. (D) Example images and histogram of integrated density (ImageJ) of iPSC-RPE cells in transwell inserts exposed to UV, p=0.5. (E) Example images of low and high risk iPSC-RPE cells after UV exposure, scale bar = 2 µm.

Supplementary figure 4

(A) Sequencing primers for SNP’s rs1061170, rs11200638 & rs10490924. Lower case nucleotides indicate sequencing tag. (B) Primary and secondary antibody list. (C) Pluripotency PCR primers.

Supplementary figure 5

(A) Sendai clearance test primers (B) qPCR primer list.
Figure 2

A

B

C

D

Low risk

High risk
Figure 4

(A) Bar graph showing the volume (µm$^3$) of lipid droplets in low-risk and high-risk groups. The P value is 0.0131.

(B) Images showing APOE and C5b-9 staining in low-risk and high-risk groups.

(C) Images showing DAPI staining in low-risk and high-risk groups.

(D) Images showing 50 µm scale markers.

(E) Graph showing the average size of lipid globules (µ$^3$). The P value is <0.0001.

(F) Images showing nuclei and Oil Red O staining in low-risk and high-risk groups.

Scale bar 200 µm.

Figure 4
Figure 5

**A** Microvilli Length

**B** Mitochondrial Area

**C** Mitochondrial Number

**D** Vacuole Number

E, F: Images showing cellular structures with annotations for low and high risk groups.
Figure 6

Fibroblasts

A

LC3

p62

LC3

p62

10 μM

B

C

D

E

Number of LC3 vesicles/cell

Number of p62 positive

p62 intensity/cell A.U.

iPSC-RPE

F

LC3

p62

LC3

p62

10 μM

G

H

I

J

Figure 6
Supplementary Figure 1

| Age | Sex  | CFH       | HTRA1      | ARMS2      |
|-----|------|-----------|------------|------------|
| 77  | Female | F018 | rs1061170 | rs11200638 | rs10490924 |
| 63  | Male  | F116 |           |            |            |
| 77  | Male  | F180 |           |            |            |
| 87  | Female | F181 |           |            |            |

Supplementary Figure 1
Supplementary Figure 2

A

|        | SSEA4 | OCT4 | DAPI |
|--------|-------|------|------|
| F018   |       |      |      |
| F116   |       |      |      |
| F180   |       |      |      |
| F181   |       |      |      |

B

|        | H9    | F018 | F116 | F180 | F181 |
|--------|-------|------|------|------|------|
| GAPDH  |       |      |      |      |      |
| RLP13A |       |      |      |      |      |
| NANOG  |       |      |      |      |      |
| KLF4   |       |      |      |      |      |
| c-MYC  |       |      |      |      |      |
| SOX2   |       |      |      |      |      |

C

|        | TRA-60 |       |       |
|--------|--------|-------|-------|
|        |        | TrA-60 |       |
|        |        | TrA-60 |       |
|        |        | TrA-60 |       |

D

|        | DAPI | MERGE |
|--------|------|-------|
| TUJ1   |      |       |
| SMA    |      |       |
| AFP    |      |       |

E

| Neural epitheli | Cartilage and gut |
|----------------|-------------------|
| Ectoderm       | Mesoderm and Endoderm |

F

|        | F018 | F116 | F180 | F181 |
|--------|------|------|------|------|
| +ve    |      |      |      |      |
| -ve    |      |      |      |      |
| C-MYC  |      |      |      |      |
| KOS    |      |      |      |      |
| SEV    |      |      |      |      |
| KLF    |      |      |      |      |
| GAPDH  |      |      |      |      |

G

| Fibroblasts |
|-------------|
| iPSC        |

Supplementary Figure 2
Supplementary Figure 3

A

![Image of Supplementary Figure 3](image_url)

B

| Disease                                | Gene ID                                                                 |
|----------------------------------------|------------------------------------------------------------------------|
| Macular degeneration                   | C57B/A458J, APOE5, FBN1/5, C2                                           |
| Disorder of glycosylation              | ALG16B, AMG17J, ALO65, 5SC5, C1, ALG2, ALG3, ALG12, ALG1, MPDU1         |
| Diabetes mellitus, type 2              | ABC16B, RS1, WFS1, GCR, INSR, RS2, GCF, NEUROD1, A1, AKT2, GPD2, HNF4A, PPARG, GF2BP2 |

Table of overrepresented disease related genes in AMD-IPSC-RPE cells.

C

![Gene expression graph](image_url)

D

![High vs Low risk integrated density graph](image_url)

E

![Low Risk vs High Risk image](image_url)

Supplementary Figure 3
### Supplementary Figure 4

#### Table of SNP sequencing primers

| Gene               | Primer | Sequence                                      |
|--------------------|--------|-----------------------------------------------|
| CFH rs1061170      | Fwd.   | 5'–gtagctggagcgccaggtcagtagtacGGTAACTTTAGTTCCTCCCTCAG–3' |
|                   | Rev.   | 5'–cagctccctccgatctctcagccaggctgatctctcag–3'       |
| HTRA1 rs11200638   | Fwd.   | 5'–gtagctggagcgccaggtcagtagtacCATGCCACCCACAAACAAACT–3' |
|                   | Rev.   | 5'–cagctccctccgatctctcagccaggctgatctctcag–3'       |
| ARMS2 rs10490324   | Fwd.   | 5'–gtagctggagcgccaggtcagtagtacAGTGACAAACAGAGAGGAAGCA–3' |
|                   | Rev.   | 5'–cagctccctccgatctctcagccaggctgatctctcag–3'       |

#### Table of primary and corresponding secondary antibodies used.

| Antibody Type               | Primary Antibody | Secondary Antibody | Manufacturer 1 | Manufacturer 2 |
|-----------------------------|------------------|--------------------|----------------|---------------|
| Tra-1-60-FITC               | Millipore, UK    | N/A                | N/A            | N/A           |
| Alexa Fluor® 647 anti-Nanog Antibody | Cell Signalling | N/A                | N/A            | N/A           |
| Anti-OCT4                   | Abcam            | Alexa Fluor®488 goat anti-rabbit | Thermo Scientific |
| Human/Mouse SSEA-4 Northern Lights™ NAL83 | R&D Systems     | N/A                | N/A            | N/A           |
| Mouse anti-AFP (lgG1)       | Thermo Scientific | Alexa Fluor®488 goat anti-mouse lgG1 | Thermo Scientific |
| Rabbit Anti –TU1            | Thermo Scientific | Alexa Fluor®647 donkey anti-rabbit | Thermo Scientific |
| Mouse anti-SMA (lgG2a)      | Thermo Scientific | Alexa Fluor®555 goat anti-mouse lgG2a | Thermo Scientific |
| Goat anti-FH                | Millipore, UK    | Rabbit anti-Goat lgG-HRP | Millipore |
| Sheep anti-CF1              | Abcam            | Rabbit anti-Sheep HRP | Abcam |
| Rabbit anti-C3a             | Abcam, UK        | Goat anti-Rabbit HRP | Abcam |
| Mouse Anti-RPE65            | Abcam, UK        | Alexa Fluor®647 goat anti-mouse lgG1 | Thermo Scientific |
| Rabbit Anti-ZO-1            | Invitrogen       | Cyt Anti-Rabbit | Invitrogen |
| Rabbit Anti-LC3             | Cell Signalling  | Alexa Fluor®488 goat anti-Rabbit | Invitrogen |
| Mouse Anti-p62              | BD Biosciene     | Alexa Fluor®594 goat anti-mouse | Invitrogen |
| Mouse Anti-CsB-9            | Dako, UK         | Alexa Fluor®647 goat anti-mouse lgG1 | Thermo Scientific |
| Donkey Anti-APOE             | Abcam, UK        | Alexa Fluor® 488 Donkey Anti-Goat lgG H&L | Abcam |
| Mouse Anti-CRALBP           | Genetex, USA     | Alexa Fluor®488 goat anti-mouse | Thermo Scientific |
| Mouse Anti-IBEST1           | Abcam, UK        | Cyt Anti-mouse | Invitrogen |
| Rabbit Anti-Na+ K^⁺-ATPase  | Abcam, UK        | N/A                | N/A            | N/A           |

#### Table of pluripotency PCR primers used.

| Gene   | Primer | Sequence                                      |
|--------|--------|-----------------------------------------------|
| NANO5  | Fwd.   | 5'–AGAAGGCCTCAAGCACTAC–3'                     |
|        | Rev.   | 5'–GGCCGTATGTTCCTCCAGGATT–3'                 |
| OCT4   | Fwd.   | 5'–CTTGAACCCGAATGGAAAGGG–3'                  |
|        | Rev.   | 5'–GTGTATACCCAGGTGGATCTTC–3'                 |
| C-MYC  | Fwd.   | 5'–TGGCAAGCTCCAGGCCTT–3'                     |
|        | Rev.   | 5'–TGGCAAGCTCCAGGCCTT–3'                     |
| SOX2   | Fwd.   | 5'–GCCAGCTACAGGATGAGCAGGAG–3'                |
|        | Rev.   | 5'–CTGGTCTAGGATGTTGATGCTGCAGG–3'             |
### Supplementary Figure 5

#### Table A

| Gene | Primer | Sequence               |
|------|--------|------------------------|
| KLF  | Fwd.   | 5’-TTCTTCATGCCAGAGAGCC-3’ |
|      | Rev.   | 5’-CTACACAAAAGGTCCTCCAT-3’* |
| KOS  | Fwd.   | 5’-TGACAGGCATGACGCTGG-3’ |
|      | Rev.   | 5’-ACTGACAAATCTCGATG-3’ |
| SEV  | Fwd.   | 5’-GGATACATGGTGATATGACG-3’ |
|      | Rev.   | 5’-ACTACAGAAGTTAAGAGATGATGTC-3’|
| c-MYC| Fwd.   | 5’-TGACCTGAATTACGCAGGCTTG-3’ |
|      | Rev.   | 5’-TCCGACATCAAAGTCATGGATG-3’ |
| GAPDH| Fwd.   | 5’-TGACACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GGCAATGGACTTATTACGAG-3’ |

*Table of PCR primers used for sendi clearance, *Primer re-designed in house from manufacture supplied.

#### Table B

| Gene | Primer | Sequence               |
|------|--------|------------------------|
| GAPDH| Fwd.   | 5’-TGACACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GGCAATGGACTTATTACGAG-3’ |
| RPE65| Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GGCAATGGACTTATTACGAG-3’ |
| OTX2 | Fwd.   | 5’-CCTGGGCGGAGAAAGGAAGGA-3’ |
|      | Rev.   | 5’-TGAGGACCCTGCTTATGCTG-3’ |
| RLP13A| Fwd.    | 5’-CCGAGGCAAAGGACCGAAGGA-3’ |
|      | Rev.   | 5’-GGCAATGGACTTATTACGAG-3’ |
| SOD2 | Fwd.   | 5’-TGACTGACCAATCAAAAGAAC-3’ |
|      | Rev.   | 5’-TGCTGGAGGGTCATGGTCGCC-3’ |
| APOE | Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GGCAATGGACTTATTACGAG-3’ |
| C5   | Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GGCAATGGACTTATTACGAG-3’ |
| C3   | Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GGCAATGGACTTATTACGAG-3’ |
| CFI  | Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GGCAATGGACTTATTACGAG-3’ |
| CFH  | Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GGCAATGGACTTATTACGAG-3’ |
| FHL-1| Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GGCAATGGACTTATTACGAG-3’ |
| IL1B | Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GCCGACACCAATCTGACAG-3’ |
| IL1B | Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GCCGACACCAATCTGACAG-3’ |
| TNF-a| Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GCCGACACCAATCTGACAG-3’ |
| IL6  | Fwd.   | 5’-GCCGACACCAATCTGACAG-3’ |
|      | Rev.   | 5’-GCCGACACCAATCTGACAG-3’ |

*Table of qPCR primers used in this study.